Allowing APPs to sign anti-cancer treatment orders not only improves access to high-quality cancer care, it can also free up physician time to see more new patients and streamline clinic workflow.
Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!
While remote monitoring platforms have been used effectively throughout the COVID-19 pandemic to reduce the burden on patients and healthcare facilities around the country, Vanderbilt Ingram Cancer Center in Nashville, Tenn., has been using the technology in a different capacity—with its chimeric antigen receptor (CAR) T-cell therapy patients. Today, these patients are monitored 24/7 via remote technology, alerting cancer program staff of any significant changes in clinical status that would initiate a hospital admission.
Read more in "Changing the Tune for CAR T-Cell Therapy: A Music City Experience in Remote Patient Monitoring," in the Volume 38, Number 6 Oncology Issues.
Guest:
Brittney M. Baer, BSN, RN
Patient Care Coordinator
Vanderbilt University Medical Center
“One of the biggest challenges is access to care for CAR T-cell therapy patients...it’s a struggle for them [patients] to get to these larger academic medical centers and that’s a burden on patients…so, it’s very, very cool and our patients seem to really enjoy it because they don’t have to spend nearly as much time at the hospital.”
Resources:
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
June 30, 2026
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
